Thermo Fisher Scientific Inc. $TMO Position Raised by Teca Partners LP

Teca Partners LP increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 81.5% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 31,939 shares of the medical research company’s stock after buying an additional 14,339 shares during the quarter. Thermo Fisher Scientific comprises approximately 10.8% of Teca Partners LP’s portfolio, making the stock its 4th biggest position. Teca Partners LP’s holdings in Thermo Fisher Scientific were worth $15,699,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in TMO. Assetmark Inc. increased its position in shares of Thermo Fisher Scientific by 22.9% during the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after purchasing an additional 7,023 shares during the last quarter. North Dakota State Investment Board purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $7,505,000. Northstar Advisory Group LLC bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $3,250,000. Boston Trust Walden Corp increased its holdings in Thermo Fisher Scientific by 9.7% during the fourth quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock valued at $25,480,000 after buying an additional 3,873 shares during the last quarter. Finally, Xponance LLC raised its position in Thermo Fisher Scientific by 8.1% in the fourth quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock worth $34,358,000 after acquiring an additional 4,436 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.7%

TMO opened at $558.79 on Tuesday. The stock has a market cap of $207.66 billion, a price-to-earnings ratio of 30.06, a price-to-earnings-growth ratio of 2.51 and a beta of 0.87. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The firm’s fifty day moving average is $496.34 and its 200 day moving average is $512.33. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.07 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on TMO shares. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 target price on the stock. Barclays boosted their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday. Robert W. Baird decreased their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $630.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $617.14.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.